Related Experiment Video

Updated: Feb 19, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.2K

HIF2α-Targeted RNAi Therapeutic Inhibits Clear Cell Renal Cell Carcinoma

So C Wong1, Weijun Cheng2, Holly Hamilton2

  • 1Arrowhead Pharmaceuticals Inc., Madison, Wisconsin. swong@arrowheadpharma.com.

Molecular Cancer Therapeutics
|October 29, 2017
PubMed

Insights

A novel RNAi therapeutic targeting hypoxia-inducible factor 2α (HIF2α) shows promise for metastatic clear cell renal cell carcinoma (ccRCC). This approach inhibited tumor growth in a preclinical model, offering a potential new treatment for patients resistant to current therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • Metastatic clear cell renal cell carcinoma (ccRCC) often becomes refractory to standard VEGF and mTOR targeted therapies.
  • Loss of von Hippel-Lindau protein (pVHL) function in ccRCC leads to hypoxia-inducible factor 2α (HIF2α) accumulation, driving tumor growth.
  • There is a critical need for novel therapeutic strategies for advanced ccRCC.

Purpose of the Study:

  • To develop and evaluate a novel RNA interference (RNAi) therapeutic targeting HIF2α for ccRCC.
  • To assess the efficacy of this RNAi therapeutic in inhibiting ccRCC tumor growth in a preclinical setting.

Main Methods:

  • Development of an RNAi therapeutic designed to silence HIF2α.
  • Incorporation of a targeting ligand that binds to integrins αvβ3 and αvβ5, which are overexpressed in ccRCC.
  • Testing the therapeutic's efficacy in an orthotopic ccRCC xenograft mouse model.

Main Results:

  • The RNAi therapeutic successfully achieved HIF2α gene silencing.
  • Functional delivery of the therapeutic led to significant inhibition of tumor growth.
  • Tumor degeneration was observed in the treated ccRCC xenograft model.

Conclusions:

  • A HIF2α-specific RNAi therapeutic demonstrates potential as an innovative treatment for ccRCC.
  • Targeting HIF2α via RNAi offers a promising strategy for overcoming therapeutic resistance in ccRCC.
  • This approach warrants further investigation for clinical application in ccRCC patients.

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.2K
Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane05:36

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

9.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
8.0K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.0K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.8K
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
28.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K